Bio Science Innovator Twist Bioscience Delivers Improved Q1 2025 Earnings, Stock Climbs 7%

MEVHunterX · 2026-02-18T10:18:15+00:00

Twist Bioscience Corporation's stock rose 7% following its Q1 2025 earnings report, highlighting reduced losses and a 16.9% revenue increase to $103.7 million. This reflects improved operational efficiency and growing investor confidence in the company's market strategy.

MEVHunterX

2026-02-18 10:18:15

Abstract generation in progress

Twist Bioscience Corporation (TWST), a leading bio science company, captured investor attention on Monday as its stock surged approximately 7%, reaching $44.23 on the Nasdaq—up $3.28 from the previous close of $41.07. The rally followed the company’s release of 2025 first-quarter earnings, which demonstrated notable operational improvements and revenue acceleration within the competitive bio science sector.

Narrowed Losses Point to Operational Efficiency Gains

The bio science firm reported a significant reduction in quarterly losses, with Q1 net loss narrowing to $30.5 million, or $0.50 per share, compared to $31.6 million, or $0.53 per share, in the same period a year ago. This contraction in losses signals improved operational efficiency across Twist Bioscience’s bio science business lines. The per-share loss improvement of $0.03 demonstrates the company’s progress toward profitability, even as it continues investing in research and development within the bio science space.

Robust Revenue Growth Reinforces Bio Science Market Position

More impressively, Twist Bioscience’s total revenue surged to $103.7 million in Q1 2025, compared to $88.7 million in Q1 2024—representing a robust 16.9% year-over-year increase. This revenue acceleration reflects growing demand for the company’s bio science solutions and platforms, suggesting strengthened market positioning. The combination of narrowed losses and accelerating revenue growth illustrates the company’s improving financial trajectory within the dynamic bio science industry.

Market Reception Reflects Investor Confidence

The 7% stock price appreciation indicates that investors are rewarding Twist Bioscience’s financial progress. Trading within a 52-week range of $23.30 to $54.74, the stock has demonstrated significant volatility, yet the Q1 earnings response suggests growing confidence in the company’s bio science strategy and execution. The improved financial metrics provide evidence that Twist Bioscience is successfully scaling its operations while maintaining disciplined cost management—key priorities for sustainable growth in the competitive bio science sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.